Financial Performance - The company's operating revenue for 2021 was approximately ¥470.77 million, representing a year-over-year increase of 12.57% compared to ¥418.20 million in 2020[21]. - The net profit attributable to shareholders for 2021 was approximately ¥142.76 million, which is a 21.99% increase from ¥117.02 million in 2020[21]. - The net cash flow from operating activities increased by 24.29% to approximately ¥188.86 million in 2021, up from ¥151.95 million in 2020[21]. - The company's total assets as of the end of 2021 reached approximately ¥1.43 billion, a 42.12% increase from ¥1.01 billion at the end of 2020[21]. - The net assets attributable to shareholders increased by 44.10% to approximately ¥1.28 billion in 2021, compared to ¥887.36 million in 2020[21]. - The basic earnings per share for 2021 was ¥0.37, reflecting a 12.12% increase from ¥0.33 in 2020[22]. - The company's comprehensive gross margin for the reporting period is 74.85%, maintaining stability despite potential risks from rising labor costs and market competition[101]. - The gross margin for the in vitro diagnostic reagents was 74.85%, an increase of 2.40 percentage points compared to the previous year[109]. - The sales of the LiCA® series products reached 388.77 million yuan, with a gross margin of 76.74%, up 1.88 percentage points year-on-year[109]. Dividend and Capital Management - The company plans to distribute a cash dividend of 1.70 RMB per 10 shares, totaling approximately 68.17 million RMB, which represents 47.75% of the net profit attributable to shareholders for 2021[4]. - The company does not plan to increase capital through capital reserves or issue bonus shares[4]. - The company has not yet achieved profitability since its listing[3]. Research and Development - Research and development expenses accounted for 14.30% of operating revenue in 2021, an increase of 0.81 percentage points from 13.49% in 2020[22]. - Total R&D investment for the year was approximately ¥67.32 million, representing a 19.33% increase from the previous year, and accounting for 14.30% of total revenue[73]. - The company has developed over 60 products in various categories, including infectious diseases, tumors, thyroid hormones, and cardiac markers, which have received registration certificates and successfully launched for sale[76]. - The company has established a proprietary photochemical luminescence technology platform, becoming a pioneer in this field within China[44]. - The company has developed the LiCA® series diagnostic reagents based on photochemical luminescence and the CC series based on enzyme-labeled chemiluminescence, addressing major clinical testing needs in infectious diseases and tumor markers[44]. Market Position and Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[21]. - The company aims to strengthen its market share in the in vitro diagnostics industry and maintain its leadership position through continuous innovation and technology accumulation[42]. - The company is focusing on technological innovation to meet unmet medical needs, particularly in common and frequently occurring diseases[32]. - The company is actively pursuing diversification in its product lines and expanding into next-generation technologies to build a comprehensive in vitro diagnostic ecosystem[134]. - The company is focusing on developing innovative diagnostic products to meet the growing demand for domestic alternatives to imported brands, which currently hold a 70%-80% market share[128]. Governance and Compliance - The company has established a governance structure that ensures effective operation of the shareholders' meeting, board of directors, and supervisory board, maintaining investor interests[139]. - The company has established a comprehensive internal control system, ensuring effective execution and compliance, with no significant deficiencies reported during the reporting period[177]. - The company strictly adhered to information disclosure regulations, ensuring timely and accurate reporting to protect investor interests[140]. - The company has implemented a dual-channel career model for employee development, enhancing both organizational and individual capabilities through various training methods[169]. Operational Risks and Challenges - The company has detailed various operational risks in the "Management Discussion and Analysis" section of the report[3]. - The company faces risks related to new product development and registration, which typically takes 3-5 years, impacting potential future revenues if not successfully managed[94]. - The company is exposed to environmental risks due to waste generation during production, which could lead to penalties if regulations are not met[100]. - The company operates in a highly competitive in vitro diagnostic market, with significant players like Roche and Abbott, which may impact its market share and profitability[99]. Product Development and Innovation - The company has developed the LiCA® platform, which aims to compete with international brands in the chemiluminescence diagnostic market[31]. - The LiCA® Smart fully automated chemiluminescence immunoassay analyzer was successfully launched, meeting the needs of large hospitals and small to medium-sized hospitals for emergency and routine clinical immunodiagnosis[36]. - The company has established a comprehensive core technology system for in vitro diagnostics, covering reagents, instruments, and biological raw materials, significantly enhancing its independent research and development capabilities[34]. - The company has achieved a significant increase in the number of R&D personnel, from 126 to 138, indicating a focus on innovation and product development[80]. Sales and Distribution - The company operates a sales model where over 97% of revenue is generated through distributors, with strict management protocols in place for distributor qualifications and support[52]. - The company successfully participated in the centralized procurement of chemical luminescence infectious disease products in Anhui Province, replacing over ten imported brand products in major hospitals shortly after the policy implementation[33]. - The company’s products are used in over 1,000 hospitals, with more than 80% being secondary or higher-level hospitals, and over 30% being tertiary hospitals[92]. Employee and Management - The company employed a total of 632 staff members, with 220 in the parent company and 412 in major subsidiaries[167]. - The workforce includes 162 production personnel, 254 sales personnel, and 138 technical personnel[167]. - The company has established a robust compensation management system, providing competitive salaries to enhance employee motivation and stability[182]. - The company has a dedicated management training institute to enhance management capabilities and operational efficiency, with nearly 70 key management personnel participating in the program[169].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 120,882,732.99, representing a year-on-year increase of 0.55%[5] - The net profit attributable to shareholders for the same period was CNY 39,107,317.86, reflecting a growth of 2.54% compared to the previous year[5] - Total operating revenue for Q1 2022 was CNY 120,882,732.99, a slight increase of 0.55% compared to CNY 120,215,653.37 in Q1 2021[19] - Net profit for Q1 2022 reached CNY 39,107,317.86, representing an increase of 2.54% from CNY 38,138,994.23 in Q1 2021[21] - The net profit for Q1 2022 was a loss of ¥6,052,137.88, compared to a loss of ¥2,823,027.53 in Q1 2021, representing an increase in loss of 114.0%[31] Cash Flow - The net cash flow from operating activities increased significantly by 47.22%, amounting to CNY 58,921,042.84, due to increased sales collections and reduced procurement expenditures[6][10] - Cash inflow from operating activities for Q1 2022 was CNY 143,862,718.38, an increase of 10.06% compared to CNY 130,244,977.65 in Q1 2021[24] - The net cash flow from operating activities for Q1 2022 was a negative ¥4,825,094.93, compared to a negative ¥1,011,888.80 in Q1 2021[34] - Investment activities resulted in a net cash outflow of ¥152,610,099.14 in Q1 2022, compared to a net outflow of ¥69,212,760.93 in Q1 2021[34] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,470,694,840.01, showing a growth of 2.78% from the end of the previous year[6] - Total assets as of Q1 2022 amounted to CNY 1,470,694,840.01, an increase from CNY 1,430,906,695.48 in the previous year[17] - Total liabilities for Q1 2022 were CNY 149,390,178.81, a decrease from CNY 152,233,971.04 in Q1 2021[17] - Total liabilities decreased to CNY 29,828,540.71 from CNY 47,669,901.28 year-over-year[29] Research and Development - Research and development expenses totaled CNY 18,502,792.33, accounting for 15.31% of operating revenue, which is an increase of 3.06 percentage points year-on-year[6] - Research and development expenses for Q1 2022 were CNY 18,502,792.33, an increase of 25.5% compared to CNY 14,728,188.25 in Q1 2021[20] - Research and development expenses increased to ¥10,877,795.20 in Q1 2022, up 38.0% from ¥7,879,358.05 in Q1 2021[30] Shareholder Information - The company reported a total of 7,961 common shareholders at the end of the reporting period[10] - The company’s major shareholders include entities with significant stakes, such as Ningbo Yingweili and Ningbo Keboao, with ownership percentages of 79.15% and 5.40% respectively[13] - The company has established a relationship with major shareholders, including a 100% ownership by China Ping An Insurance Group in Ping An Real Estate, which directly holds 70.53% of Ping An Ankang[13] Equity and Earnings - The total equity attributable to shareholders increased by 3.33% to CNY 1,321,304,661.20 compared to the end of the previous year[6] - The basic and diluted earnings per share were both CNY 0.10, down by 9.09% year-on-year[5] - Earnings per share for Q1 2022 were CNY 0.10, down from CNY 0.11 in Q1 2021[21] Inventory and Receivables - Accounts receivable decreased to ¥33,074,579.41 from ¥35,127,292.63, showing a decline of about 5.9%[15] - Inventory levels were reported at ¥116,586,862.72, down from ¥122,362,493.25, indicating a decrease of approximately 4.7%[15] - The company’s inventory as of March 31, 2022, was CNY 32,142,005.62, a slight decrease from CNY 33,822,531.63 in the previous year[27]

Financial Performance - The company's operating revenue for Q3 2021 was ¥118,535,231.69, a decrease of 17.84% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2021 was ¥37,787,512.59, down 16.82% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥29,603,067.90, a decrease of 29.89% compared to the same period last year[5] - Total operating revenue for the first three quarters of 2021 reached ¥355,463,272.78, an increase from ¥295,657,726.42 in the same period of 2020, representing a growth of approximately 20.2%[22] - Total operating costs for the first three quarters of 2021 were ¥244,220,961.08, compared to ¥218,506,898.71 in the same period of 2020, reflecting an increase of about 11.8%[23] - Operating profit for the first three quarters of 2021 was ¥123,442,779.63, up from ¥90,075,919.16 in the same period of 2020, indicating a growth of approximately 37.0%[23] - The net profit for Q3 2021 was CNY 107,803,052.25, an increase of 40.8% compared to CNY 76,595,066.44 in Q3 2020[24] - The total comprehensive income for Q3 2021 was CNY 107,803,052.25, reflecting a 40.8% increase from CNY 76,595,066.44 in Q3 2020[25] Cash Flow and Liquidity - The cash flow generated from operating activities for the year-to-date was ¥149,520,066.42, an increase of 55.75% compared to the previous year[6] - The company's cash and cash equivalents as of September 30, 2021, were ¥176,210,193.04, down from ¥224,817,311.69 at the end of 2020, a decrease of about 21.5%[18] - Cash flow from operating activities for the first three quarters of 2021 was CNY 149,520,066.42, compared to CNY 96,001,816.24 in the previous year, indicating a growth of 55.7%[28] - The company reported a total operating cash inflow of CNY 415,628,012.48 for the first three quarters of 2021, compared to CNY 328,543,128.29 in the same period last year, marking a 26.5% increase[27] - The total operating cash outflow for the first three quarters of 2021 was CNY 266,107,946.06, compared to CNY 232,541,312.05 in the previous year, an increase of 14.4%[28] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,400,482,989.61, reflecting a 39.10% increase from the end of the previous year[6] - The company's total assets as of September 30, 2021, amounted to ¥1,400,482,989.61, compared to ¥1,006,822,552.60 at the end of 2020, representing an increase of approximately 38.9%[20] - The company's total liabilities as of September 30, 2021, were ¥156,764,434.06, up from ¥119,463,997.34 at the end of 2020, reflecting an increase of about 31.2%[20] - Total liabilities were $119,463,997.34, reflecting a decrease of $10,199,341.75 from the previous period[32] - The total current assets and liabilities indicate a stable liquidity position for the company[31][32] Shareholder Information - The total number of common stock shareholders at the end of the reporting period was 8,218[12] - The largest shareholder, Ningbo Free Trade Zone Yingweili Enterprise Management Partnership, holds 26.6% of shares, totaling 108,000,000 shares[12] - The second-largest shareholder, Shanghai Peixi Investment Management Partnership, holds 11.3% of shares, totaling 45,421,070 shares[12] - The company has a total of 22,710,530 shares held by Shenzhen Ping An Real Estate Investment Co., accounting for 5.6% of shares[12] - The report indicates that the top ten shareholders have significant interconnected relationships, with the actual controller holding substantial stakes in multiple entities[13] Research and Development - Research and development expenses totaled ¥16,759,354.04 for the quarter, a decrease of 19.99% compared to the same period last year[6] - The company has invested significantly in R&D, with R&D expenses for the first three quarters of 2021 totaling ¥48,243,992.75, compared to ¥43,641,529.46 in the same period of 2020, an increase of approximately 10.5%[23] - The company plans to continue its active investment in R&D and patent layout, focusing on various clinical applications[16] - The report highlights a significant academic paper validating the performance of the LICA® technology for progesterone quantification, emphasizing its high sensitivity and accuracy[15] - The company is focusing on expanding its product offerings in the field of hormone detection, particularly with the LICA® technology[15] - The company obtained 4 domestic Class II medical device registration certificates during the reporting period, with 17 products in the review stage and 9 in clinical trials, covering common clinical areas such as infectious diseases and tumors[16] - The company received 6 authorized patents during the reporting period, including 1 domestic invention patent and 4 design patents[17] Market Strategy - The company is exploring potential market expansion strategies to increase its footprint in the diagnostics sector[15] - The company completed its initial public offering, which contributed to the increase in total assets and equity[10] - The company is committed to enhancing its research capabilities and product development in response to market demands[15]

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, with total revenue reaching RMB 100 million, representing a growth of 25% compared to the same period last year[1]. - The company achieved operating revenue of CNY 236.93 million in the first half of 2021, representing a year-on-year increase of 56.51%[18]. - Net profit attributable to shareholders reached CNY 70.02 million, a significant increase of 124.65% compared to the same period last year, primarily driven by increased sales of the LiCA® product series[20]. - The net cash flow from operating activities was CNY 81.41 million, up 101.60% year-on-year, attributed to increased sales and collection of receivables[21]. - Basic earnings per share were CNY 0.19, reflecting a 111.11% increase from CNY 0.09 in the previous year[20]. - The company reported a significant decrease in other income by 90.88% due to reduced government subsidies received during the reporting period[91]. - The total profit before tax amounted to CNY 80,595,551.20, compared to CNY 35,814,997.73 in the previous year, showing a substantial increase[198]. - The total comprehensive income for the first half of 2021 was CNY 70,015,539.66, compared to CNY 31,166,614.41 in the previous year, reflecting overall growth[199]. Market Expansion and Product Development - The company has provided a positive outlook for the second half of 2021, projecting a revenue growth of 30% year-over-year[1]. - New product development includes the launch of the LiCA® series, which has shown promising initial sales figures, contributing to 10% of total revenue[1]. - The company is actively pursuing market expansion strategies, targeting new regions in Southeast Asia, with plans to enter three new markets by the end of 2021[1]. - The company plans to continue expanding its product offerings and market presence, focusing on innovation and strategic partnerships[21]. - The company is actively developing new products, including the LiCA® AT 5000, which is currently in the development phase[31]. - The company successfully launched the LiCA® Smart fully automated chemiluminescence immunoassay analyzer in the first half of 2021, which is the first of its kind in China to meet the "Expert Consensus on Emergency Testing Capability Construction and Standards" (2020 version)[72]. Research and Development - The company has committed to increasing R&D investment by 20% in 2022 to enhance product innovation and technological advancements[1]. - Research and development expenses accounted for 13.29% of operating revenue, a decrease of 1.70 percentage points compared to the previous year[20]. - The company achieved a 38.73% increase in research and development (R&D) expenses, totaling ¥31,484,638.71 compared to ¥22,695,171.07 in the previous period[55]. - The number of R&D personnel increased to 123, accounting for 19.81% of the total workforce[61]. - The company has successfully advanced 19 projects into regulatory review and 11 into clinical stages, covering infectious diseases, thyroid function, reproductive health, tumor markers, and autoimmune diseases[52]. Financial Stability and Investments - The company has maintained a strong balance sheet, with total assets amounting to RMB 500 million, ensuring financial stability for future investments[1]. - The company's total assets at the end of the reporting period were CNY 1.35 billion, a 34.56% increase from the previous year-end[19]. - The company's net assets attributable to shareholders increased to CNY 1.21 billion, up 35.90% from the previous year-end[19]. - Cash assets at the end of the period reached 406,921,481.56, representing 30.04% of total assets, an increase of 81.00% compared to the previous year[93]. - The company has committed to a share buyback program to stabilize stock prices, with an allocation of 200 million RMB[113]. Risks and Challenges - The management has identified key risks, including regulatory changes and market competition, and has outlined mitigation strategies in the report[1]. - Increased competition in the in-vitro diagnostic market from both domestic and international companies poses a risk to market share and profitability[84]. - The company faces risks related to product quality and regulatory compliance, which could impact sales performance and brand image[83]. - The company must adapt to healthcare reforms such as "two-invoice system" and "volume-based procurement" to avoid potential declines in operating performance[86]. Shareholder Commitments and Governance - The company has committed to maintaining shareholding arrangements for major shareholders for 36 months post-IPO[112]. - The company has ensured compliance with commitments related to shareholding and reduction arrangements for significant shareholders[112]. - The company will comply with relevant laws and regulations regarding the reduction of shareholdings after the lock-up period[119]. - The company will adhere to regulations regarding shareholding and reduction commitments, including those from the China Securities Regulatory Commission and the Shanghai Stock Exchange[126]. - The company will bear compensation responsibilities for any losses caused to investors due to non-fulfillment of commitments[130]. Environmental Management - The company has implemented various environmental management systems to effectively manage emissions during production, including adherence to national standards for air pollutants and wastewater treatment[106]. - The company is actively reducing carbon emissions through clean energy and renewable energy technologies, aiming to improve energy efficiency[109]. - There are no reported administrative penalties related to environmental issues during the reporting period[106]. Legal Matters - The company is involved in significant litigation, including a case where it is accused of infringing on trade secrets, with a claim for damages amounting to RMB 6.8 million and additional costs of RMB 1 million[153]. - The company has ongoing litigation with the Supreme People's Court regarding a trade secret infringement case, which is currently under review[153]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties during the reporting period[152].

Financial Performance - Operating income rose by 103.52% to CNY 120,215,653.37 year-on-year[5] - Net profit attributable to shareholders increased by 253.69% to CNY 38,138,994.23 compared to the same period last year[5] - Basic and diluted earnings per share both increased by 253.69% to CNY 0.11[5] - Operating profit for Q1 2021 was ¥44,471,576.60, up from ¥12,962,487.05 in Q1 2020, reflecting a growth of 243.5%[30] - Net profit for Q1 2021 amounted to ¥38,138,994.23, compared to ¥10,783,085.91 in Q1 2020, representing an increase of 253.5%[30] Cash Flow - Net cash flow from operating activities surged by 817.53% to CNY 40,023,264.03 year-on-year[5] - Cash flow from operating activities for Q1 2021 was ¥40,023,264.03, a substantial increase from ¥4,362,069.13 in Q1 2020[38] - The net cash flow from operating activities was -¥1,011,888.80, improving from -¥12,210,391.01 in the same period last year[40] Assets and Liabilities - Total assets increased by 7.31% to CNY 1,080,465,148.40 compared to the end of the previous year[5] - Total liabilities rose to CNY 154,967,598.90 from CNY 119,463,997.34, which is an increase of approximately 29.7%[22] - The company's total liabilities included a new lease liability of ¥29,298,095.26, reflecting the impact of new leasing regulations[15] - The company's current assets totaled CNY 745,371,829.51, compared to CNY 702,339,971.46 at the end of 2020, indicating an increase of about 6.1%[20] Research and Development - R&D expenses accounted for 12.25% of operating income, a decrease of 5.74 percentage points from the previous year[7] - Research and development expenses increased by 38.57% to ¥14,728,188.25, up from ¥10,628,422.89, reflecting the company's commitment to innovation[15] - R&D expenses increased to ¥7,879,358.05 in Q1 2021, up from ¥5,557,862.73 in Q1 2020, reflecting a focus on innovation[33] Shareholder Information - The total number of shareholders at the end of the reporting period was 16[10] - The largest shareholder, Ningbo Free Trade Zone Yingweili Enterprise Management Partnership, holds 30.00% of shares[10] Other Financial Metrics - The weighted average return on equity rose by 2.97 percentage points to 4.21%[5] - The company reported a total of CNY 1,508,107.19 in non-recurring gains and losses[9] - The company reported a substantial increase in income tax expenses, which rose by 450.86% to ¥6,254,697.46 from ¥1,135,442.34[15] - Investment income decreased by 59.79% to ¥1,385,096.96, down from ¥3,444,391.01, indicating a decline in returns from financial products[15] Changes in Assets - Other current assets rose significantly by 95.34% to ¥14,078,698.19, compared to ¥7,207,299.59 in the previous period[15] - The company's inventory increased to CNY 107,312,731.75 from CNY 98,672,713.99, marking an increase of about 8.3%[20] - The company reported a non-current asset total of CNY 335,093,318.89, up from CNY 304,482,581.14, indicating an increase of about 10.1%[21] Compliance and Standards - The company implemented a new leasing standard starting in 2021, affecting the financial statements[42] - The company adopted the new leasing standard effective January 1, 2021, which did not significantly impact financial status or cash flows[47]